Literature DB >> 22975369

Ready, set, go: the EGF receptor at the pancreatic cancer starting line.

Rushika M Perera1, Nabeel Bardeesy.   

Abstract

Acinar-to-ductal metaplasia (ADM) results from pancreatic injury or KRAS activation, and is an early step in pancreatic cancer progression. In this issue of Cancer Cell, Ardito and colleagues and Navas and colleagues demonstrate that ADM- and KRAS-driven pancreatic cancer require EGFR signaling, revealing a mechanism for developmental reprogramming that primes tumorigenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22975369      PMCID： PMC3564545          DOI： 10.1016/j.ccr.2012.08.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

Review 1.  Signaling on the endocytic pathway.

Authors:  Mark von Zastrow; Alexander Sorkin
Journal:  Curr Opin Cell Biol       Date:  2007-07-26       Impact factor: 8.382

Review 2.  Pancreatic ductal cells in development, regeneration, and neoplasia.

Authors:  Maximilian Reichert; Anil K Rustgi
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.

Authors:  Anna L Means; Ingrid M Meszoely; Kazufumi Suzuki; Yoshiharu Miyamoto; Anil K Rustgi; Robert J Coffey; Christopher V E Wright; Doris A Stoffers; Steven D Leach
Journal:  Development       Date:  2005-07-14       Impact factor: 6.868

4.  Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis.

Authors:  Yoshiharu Miyamoto; Anirban Maitra; Bidyut Ghosh; Ulrich Zechner; Pedram Argani; Christine A Iacobuzio-Donahue; Virote Sriuranpong; Tatsuya Iso; Ingrid M Meszoely; Michael S Wolfe; Ralph H Hruban; Douglas W Ball; Roland M Schmid; Steven D Leach
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

5.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

6.  Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells.

Authors:  Martin Wagner; Christoph K Weber; Frank Bressau; Florian R Greten; Volker Stagge; Matthias Ebert; Steven D Leach; Guido Adler; Roland M Schmid
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

7.  Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Authors:  Antonio Jimeno; Aik Choon Tan; Jordy Coffa; N V Rajeshkumar; Peter Kulesza; Belen Rubio-Viqueira; Jenna Wheelhouse; Begoña Diosdado; Wells A Messersmith; Christine Iacobuzio-Donahue; Anirban Maitra; Marileila Varella-Garcia; Fred R Hirsch; Gerrit A Meijer; Manuel Hidalgo
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

8.  Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Authors:  Eric A Collisson; Anguraj Sadanandam; Peter Olson; William J Gibb; Morgan Truitt; Shenda Gu; Janine Cooc; Jennifer Weinkle; Grace E Kim; Lakshmi Jakkula; Heidi S Feiler; Andrew H Ko; Adam B Olshen; Kathleen L Danenberg; Margaret A Tempero; Paul T Spellman; Douglas Hanahan; Joe W Gray
Journal:  Nat Med       Date:  2011-04-03       Impact factor: 53.440
  8 in total
  14 in total

1.  Commentary: CHIPping away pancreatic tumors?

Authors:  Atul D Joshi; John D Catravas
Journal:  Ann Transl Med       Date:  2014-11

Review 2.  Molecular therapeutics in pancreas cancer.

Authors:  Vignesh Narayanan; Colin D Weekes
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

3.  Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1.

Authors:  Sripathi M Sureban; Dongfeng Qu; Courtney W Houchen
Journal:  Curr Pharmacol Rep       Date:  2015-08-01

4.  Human pancreatic cancer progression: an anarchy among CCN-siblings.

Authors:  Sushanta K Banerjee; Gargi Maity; Inamul Haque; Arnab Ghosh; Sandipto Sarkar; Vijayalaxmi Gupta; Donald R Campbell; Daniel Von Hoff; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2016-08-19       Impact factor: 5.782

5.  Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.

Authors:  Emily S Humphrey; Shih-Ping Su; Adnan M Nagrial; Falko Hochgräfe; Marina Pajic; Gillian M Lehrbach; Robert G Parton; Alpha S Yap; Lisa G Horvath; David K Chang; Andrew V Biankin; Jianmin Wu; Roger J Daly
Journal:  Mol Cell Proteomics       Date:  2016-06-03       Impact factor: 5.911

Review 6.  Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.

Authors:  Arkadiusz Gzil; Izabela Zarębska; Wiktor Bursiewicz; Paulina Antosik; Dariusz Grzanka; Łukasz Szylberg
Journal:  Mol Biol Rep       Date:  2019-09-05       Impact factor: 2.316

7.  SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.

Authors:  Yu-Wen Chen; Pi-Jung Hsiao; Ching-Chieh Weng; Kung-Kai Kuo; Tzu-Lei Kuo; Deng-Chyang Wu; Wen-Chun Hung; Kuang-Hung Cheng
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

8.  The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling.

Authors:  Carole M Tactacan; Yu Wei Phua; Ling Liu; Luxi Zhang; Emily S Humphrey; Mark Cowley; Mark Pinese; Andrew V Biankin; Roger J Daly
Journal:  Mol Cancer       Date:  2015-07-29       Impact factor: 27.401

9.  DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.

Authors:  Sripathi M Sureban; Randal May; Dongfeng Qu; Nathaniel Weygant; Parthasarathy Chandrakesan; Naushad Ali; Stan A Lightfoot; Panayotis Pantazis; Chinthalapally V Rao; Russell G Postier; Courtney W Houchen
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.

Authors:  S Diersch; M Wirth; C Schneeweis; S Jörs; F Geisler; J T Siveke; R Rad; R M Schmid; D Saur; A K Rustgi; M Reichert; G Schneider
Journal:  Oncogene       Date:  2015-11-23       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.